<DOC>
	<DOCNO>NCT02117648</DOCNO>
	<brief_summary>The purpose study ass body handle LY2835219 give another drug call clarithromycin . The study doctor measure amount LY2835219 absorb blood stream time take remove LY2835219 body . The safety tolerability drug study . Each participant complete 2 study period fix order . After screen , Period 1 last approximately 8 day Period 2 last approximately 15 day . Participants complete Period 2 may continue receive LY2835219 28-day cycle discontinuation criterion meet .</brief_summary>
	<brief_title>A Study LY2835219 Participants With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Have histological cytological evidence cancer ( solid tumor ) advance and/or metastatic Have performance status 0 2 Eastern Cooperative Oncology Group ( ECOG ) scale No symptomatic central nervous system ( CNS ) malignancy metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>advanced cancer</keyword>
	<keyword>metastatic cancer</keyword>
</DOC>